Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
P11217
UPID:
PYGM_HUMAN
Alternative names:
Myophosphorylase
Alternative UPACC:
P11217; A0AVK1; A6NDY6
Background:
Glycogen phosphorylase, muscle form, also known as Myophosphorylase, plays a pivotal role in glycogen catabolism. It catalyzes the phosphorolytic cleavage of glycogen, producing glucose-1-phosphate, essential for cellular and organismal glucose homeostasis.
Therapeutic significance:
Linked to Glycogen storage disease 5, characterized by exercise intolerance and muscle weakness, understanding the role of Glycogen phosphorylase could unveil new therapeutic strategies.